General Range

Azipro 250

Enorm Med Pharma Pvt. Ltd.Panchkula, Haryana

Price on request/100 · MOQ 100 boxes

Azipro 250 Tablets, bearing Cipla branding on the packaging, contain Azithromycin 250 mg, a macrolide antibiotic prescribed for the treatment of certain bacterial infections caused by susceptible microorganisms.

Azithromycin works by inhibiting bacterial protein synthesis, helping prevent the growth and multiplication of infection-causing bacteria. It is prescribed for selected respiratory tract infections, bacterial throat infections, sinusitis, ear infections, community-acquired pneumonia and certain skin and soft tissue infections.

Azipro 250 Tablets may also be prescribed for specific sexually transmitted bacterial infections when clinically appropriate. The medicine is intended for bacterial infections and is not effective against viral illnesses.

The recommended dosage and treatment duration depend on the type of infection, bacterial susceptibility and the patient's medical condition. Azipro 250 Tablets should be taken strictly according to a registered medical practitioner's prescription.

CategoryGeneral Range

Min. Order100 boxes

Supplied byEnorm Med Pharma Pvt. Ltd.

CertificationWHO-GMP, ISO

Prices are indicative and set by the listing company. Confirm net rates, packing and stock availability directly with the supplier.

View Company

Specifications

Composition: Azithromycin Tablets IP 250 mg
Packaging Type: Tablets
Packaging Size: 6 Tablets
Dosage Form: Tablet
Treatment: Treatment of selected sexually transmitted bacterial infections under medical supervision.
Shelf Life: 24 Months
Storage: Store below 30°C, protect from light & moisture
Certification: WHO-GMP, ISO

Company Info

Enorm Med Pharma Pvt. Ltd.Panchkula, Haryana

View Full Profile

Enorm Med Pharma Private Limited is an Indian pharmaceutical company based in Panchkula, Haryana, specializing in the manufacture, trade, wholesale, and export of a wide range of pharmaceutical formulations.

Company Overview

• Incorporation / Establishment: Originally started as a proprietorship in 2021, later incorporated as a private limited company on April 9, 2023 (CIN: U46497HR2023PTC110540).
• Registered Address: SCO 272, Sector-20, Panchkula, Haryana – 134116, India.
• Directors / Leadership: Sukhinder Jindal and Gurpreet Jindal.
• Certifications: ISO 9001:2015 and WHO-GMP compliant operations/standards.
• Business Model: PCD (Propaganda Cum Distribution) Pharma Franchise, third-party manufacturing, wholesale distribution, and domestic/global supply.

Product Portfolio

Enorm Med Pharma deals in diverse therapeutic segments and dosage forms, including:
• Dosage Forms: Tablets, capsules, softgelatin capsules, syrups, dry syrups, injections (vials), and ointments.
• Therapeutic Ranges: Anti-infectives, cardiac, diabetic, dermatology, and general wellness/herbal formulas.
• Notable Branded Products: Azeenorm (Azithromycin), Diclonorm, Enomzole-D, Levonorm, Pantenorm, Norsunate (Artesunate injections), and Mebenorm.